Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide was the first drug of the GLP-1 family to reach pharmacies, approved in 2005 as Byetta, a twice-daily injection for type 2 diabetes.^[9][4] It was never approved for weight loss, and it produces much less of it than semaglutide or tirzepatide: in a 56-week head-to-head trial, people on weekly exenatide lost 1.9 kg against 5.6 kg on semaglutide.^[12] Both brand versions, Byetta and the weekly Bydureon BCise, have since been discontinued in the US.^[4][5] What is left is one generic of the twice-daily form.^[6]

What exenatide is

Exenatide is a lab-made version of exendin-4, a 39-amino-acid peptide first isolated from the venom of the Gila monster (Heloderma suspectum).^[8] The Byetta label describes it as “a synthetic peptide, GLP-1 receptor agonist, that was originally identified in the lizard Heloderma suspectum.”^[1] It acts on the same receptor as the body’s own GLP-1 hormone, raising insulin when blood sugar is high, lowering glucagon and slowing how fast the stomach empties.

When FDA approved Byetta in April 2005, its makers, Amylin and Lilly, called it “the first in a new class of medicines known as incretin mimetics.”^[9] Every GLP-1 drug since, from liraglutide to semaglutide, belongs to the class it opened. Tirzepatide acts on GLP-1 too, plus a second hormone receptor, GIP.^[14]

Byetta vs Bydureon: twice a day or once a week

Exenatide came in two forms. Byetta is the original solution in a pen, injected twice a day. It does not last long in the body: the label gives a mean half-life of 2.4 hours, with the drug measurable for about 10 hours after a dose.^[1] That is why it is taken twice, within the hour before the morning and evening meals.

Bydureon packs the same molecule into tiny dissolving microspheres that release it slowly, so one 2 mg injection lasts a week. The original Bydureon kit was withdrawn from sale in March 2021, and its successor, the Bydureon BCise autoinjector, became the only weekly version.^[4] In the trial that set the two side by side, DURATION-1, the weekly form lowered HbA1c more than twice-daily Byetta (1.9 against 1.5 percentage points over 30 weeks), with similar weight loss.^[10]

The table draws on the three labels^[1][2][3] and FDA’s Orange Book.^[6]

Is exenatide approved for weight loss?

No. Every exenatide label carries the same type 2 diabetes indication. Byetta’s reads, in full:

BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

— Byetta prescribing information, section 1

Amneal’s generic carries the same wording.^[3] Bydureon BCise extended it to “adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.”^[2] None of them mentions weight management. The GLP-1 drugs approved for weight loss are higher-dose versions of other molecules: tirzepatide (Zepbound), semaglutide (Wegovy) and liraglutide (Saxenda).

How much weight people lose on exenatide

Weight loss was always a side benefit of exenatide, and a modest one. In Byetta’s 24-week monotherapy trial, people with type 2 diabetes starting near 86 kg lost 2.9 kg on the 10 mcg dose against 1.5 kg on placebo.^[1] The largest effect came in a 24-week trial of people with obesity but no diabetes, who used twice-daily exenatide alongside a lifestyle program: they lost 5.1 kg against 1.6 kg on placebo, a difference of 3.3% of body weight.^[11]

The cleanest comparison is SUSTAIN 3, which randomized 813 people with type 2 diabetes to weekly exenatide 2 mg or weekly semaglutide 1 mg for 56 weeks. Semaglutide took off 5.6 kg, exenatide 1.9 kg, a gap of 3.8 kg. Semaglutide also lowered HbA1c more, by 1.5 against 0.9 points.^[12] And 1 mg is the diabetes dose of semaglutide (Ozempic), not the 2.4 mg weight-loss dose.

Against liraglutide, weekly exenatide also lost on blood sugar: in DURATION-6, once-daily liraglutide lowered HbA1c by 1.48 points against 1.28, and exenatide missed its target of being shown no worse.^[13]

Tirzepatide has never been tested directly against exenatide. It was tested against semaglutide 1 mg in SURPASS-2, where it took off an extra 1.9 to 5.5 kg depending on dose.^[14] Since semaglutide already beat exenatide by nearly 4 kg in SUSTAIN 3, the order of the three is not in doubt, even if the exact gap between tirzepatide and exenatide has never been measured. The trial is walked through in our SURPASS-2 deep dive.

Sources: DURATION-1,^[10] DURATION-6,^[13] SUSTAIN 3^[12] and SURPASS-2.^[14]

Side effects and warnings

Exenatide’s side effects are the familiar GLP-1 set, led by nausea. Byetta’s label lists the most common as “nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia,” and adds that “nausea usually decreases over time.”^[1] Starting at 5 mcg and stepping up after a month is meant to blunt it.

The weekly form traded some stomach trouble for skin trouble. Bydureon BCise’s most common side effects were “injection-site nodule, nausea.”^[2] In SUSTAIN 3, injection-site reactions hit 22.0% of people on weekly exenatide against 1.2% on semaglutide, while stomach side effects were less common on exenatide (33.3% against 41.8%).^[12] DURATION-6 found the same pattern against liraglutide: nausea in 9% on weekly exenatide against 21%.^[13]

• Thyroid tumors (weekly form only). Bydureon BCise carries a boxed warning: the extended-release drug caused thyroid C-cell tumors in rats, and the label says no one knows yet whether it does the same in humans, medullary thyroid carcinoma (MTC) included. Anyone who has had MTC, has a relative who had it, or has MEN 2 must not take it.^[2] Byetta has no boxed warning. Our GLP-1 thyroid cancer review covers what the human data show.
• Pancreatitis. Both labels warn of acute pancreatitis and tell you to stop exenatide when pancreatitis is suspected.^[1][2]
• Low blood sugar with other drugs. Exenatide alone rarely causes it, but the risk rises with a sulfonylurea or insulin, whose dose may need to come down.^[1]
• Kidneys. Byetta is “not recommended for use in patients with end-stage renal disease or severe renal impairment (creatinine clearance <30 mL/min).”^[1]
• A rare blood reaction. Exenatide can trigger immune-mediated thrombocytopenia, a drop in platelets that can cause serious bleeding; anyone who has had it from an exenatide product must not take one again.^[1]

On the heart, exenatide is the GLP-1 that did not show a benefit. EXSCEL followed 14,752 people with type 2 diabetes for a median of 3.2 years. Heart attack, stroke or cardiovascular death occurred in 11.4% on weekly exenatide and 12.2% on placebo, a difference that fell just short of significance. The trial did show the drug was safe for the heart, and found no rise in pancreatitis, pancreatic cancer or medullary thyroid cancer.^[15] Our EXSCEL deep dive explains why it is the trial to remember when someone says all GLP-1s protect the heart.

Can you still get exenatide in the US?

Only the twice-daily form, and only as a generic. AstraZeneca told FDA on August 16, 2024 that it planned to permanently stop marketing both Byetta and Bydureon BCise.^[4] UnitedHealthcare told prescribers that Byetta was discontinued on October 25, 2024 and Bydureon BCise on October 28, 2024.^[5] FDA’s Orange Book now lists every Byetta and Bydureon product as discontinued.^[6]

Amneal’s generic is the exception. FDA approved it on November 19, 2024 as a copy of Byetta, in the same 5 mcg and 10 mcg pens.^[6][7] It is the only exenatide the Orange Book lists as an active prescription product, and FDA now names it as the reference version that future generics must match.^[6] Its label was last updated on DailyMed in June 2026.^[3] Its product listing also carries marketing end dates for the two pens in mid-2027, so ask your pharmacy whether it can order the generic before counting on it.^[3]

Insurers have steered people to other GLP-1s. UnitedHealthcare’s preferred alternatives for its commercial plans were Mounjaro, Ozempic, Rybelsus, Trulicity and generic liraglutide.^[5]

Exenatide and Parkinson’s disease

Exenatide drew a second wave of interest from Parkinson’s research. A 2017 trial of 62 people with moderate Parkinson’s found that those on weekly exenatide for 48 weeks scored 3.5 points better on a motor-symptom scale than those on placebo, and the gap held after the drug stopped.^[16] It was small and run at one center, so a phase 3 trial followed.

That trial, Exenatide-PD3, was published in The Lancet in February 2025. It randomized 194 people across six UK hospitals to weekly exenatide 2 mg or placebo for 96 weeks. Motor scores worsened by 5.7 points on exenatide and 4.5 on placebo, with no meaningful difference between them. The authors wrote: “We found no evidence to support exenatide as a disease-modifying treatment for people with Parkinson’s disease.”^[17] The drug was safe and well tolerated, and the authors suggested drugs that reach the brain better, or specific subgroups of patients, may still be worth testing. For exenatide itself, the answer is negative.

Where exenatide fits now

Exenatide matters more as history than as a choice. It proved that a GLP-1 drug could control blood sugar and bring weight down a little, and every drug that followed was built to do both better. If you take the generic for diabetes and it controls your blood sugar, whether to switch is something to work out with your prescriber; these trials do not decide it for you. If weight loss is the goal, the drugs approved for it are the ones to ask about: in the one head-to-head trial, even semaglutide’s diabetes dose took off about three times as much weight as weekly exenatide.^[12] Our GLP-1 pipeline tracker covers what comes next.

Older drugs are not always the weaker choice. In a review of treatments for children and teens, an older combination came out ahead of semaglutide on how many patients responded, a story told in the old, cheap drug keeps winning. Exenatide also showed up in that review, with a smaller effect than the newer drugs.